Drug Profile

Licaminlimab - Novartis/Oculis Pharma

Alternative Names: ESBA-1622; LME-636; OCS-02

Latest Information Update: 18 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ESBATech
Developer Alcon; Oculis Pharma
Class Anti-inflammatories; Eye disorder therapies; Immunoglobulin Fv fragments
Mechanism of Action Tumour necrosis factor alpha inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Dry eyes; Uveitis

Most Recent Events

08 May 2025 Oculis Pharma plans to initiate first registrational trial in second half of 2025
15 Apr 2025 Oculis Pharma plans a phase II/III trial for Dry eyes (Ophthalmic), in second half of 2025
11 Mar 2025 Oculis conducts an end-of-phase II meeting with the US FDA for Licaminlimab phase-III trial initiation for Dry eyes

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com